AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Sarcopenia and Related Factors in Patients With Multiple Sclerosis

Recruitingn/aAges 18 Years - anyAllSelcuk University
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Multiple Sclerosis (MS) is a chronic disease affecting the central nervous system, exhibiting autoimmune and neurodegenerative properties. Neurological deficits, mobility limitations, and decreased muscle strength are commonly observed in MS patients as the disease progresses. The literature indicates that low physical activity levels and neurological deficits in individuals with MS can lead to decreased muscle mass and functional losses. Sarcopenia is a condition characterized by decreased skeletal muscle mass and strength associated with aging and chronic diseases, and studies on the prevalence of sarcopenia in MS patients are limited. Recent studies have revealed a high prevalence of sarcopenia in MS patients, which can have negative effects on physical performance, quality of life, and disease progression. Low muscle mass in MS patients can accelerate the loss of motor function and

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Being 18 years of age or older, * Having been diagnosed with Multiple Sclerosis (confirmed by a neurologist), * Being in a stable phase of the disease (having not had an attack in the last 3 months), * Having preserved walking ability (EDSS score โ‰ค6.5), * Being able to give informed consent to participate in the study. Exclusion Criteria: * Having another neuromuscular disease. * Having developed significant muscle loss within the last 6 months due to use of corticosteroids or immunosuppressive therapy. * Having systemic diseases that can cause muscle loss, such as cancer, rheumatic diseases, or severe metabolic disorders. * Having undergone major surgery or a history of serious trauma within the last 3 months. * Being pregnant or breastfeeding.
๐Ÿ’Š

What it tests

  • Clinical Assessments
๐Ÿ“

Where

1 site
Selcuk University Faculty of Medicine Hospital MS Life Center
Konya, Turkey (Tรผrkiye)
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy